Novel HDGF/HIF-1α/VEGF Axis in Oral Cancer Impacts Disease Prognosis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Nov 13

PMID 31711427

Citations 20

Authors

Yu-Wei Lin

Shih-Tsung Huang

Jian-Ching Wu

Tian-Huei Chu

Shih-Chung Huang

Ching-Chih Lee

Ming-Hong Tai

Affiliations

Soon will be listed here.

Abstract

Background: Hepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer. The current study was designed to elucidate the regulatory mechanism between HDGF and vascular endothelial growth factor (VEGF) and the clinical impact of oral cancer.

Methods: TCGA data and surgical samples from oral cancer patients were used for the clinicopathological parameter and survival analysis. Human oral cancer SCC4 and SAS cells were treated with recombinant HDGF protein. VEGF gene expression and protein level were analyzed by RT-PCR, Western blotting, and enzyme-linked immunosorbent assay. The signaling pathways for regulating VEGF expression were investigated. The nucleolin neutralizing antibody and HIF-1α inhibitor were applied to SCC4 cells to investigate their effects on the HDGF-stimulated VEGF pathways.

Results: TCGA and immunohistochemical analysis revealed a positive correlation between HDGF and VEGF expression in oral cancer tissues. Recombinant HDGF significantly increased VEGF gene and protein expression in oral cancer SCC4 cells in a dose-dependent manner. HDGF enhanced the phosphorylation levels of AKT and IkB and the protein level of HIF-1α and NF-κB. The nucleolin-neutralizing antibody abolished HDGF-stimulated HIF-1α, NF-κB and VEGF protein expression in SCC4 cells. The HIF-1α inhibitor antagonized the HDGF-induced VEGF gene expression. High VEGF expression was strongly correlated with HDGF expression, advanced disease, and poor survival.

Conclusion: This study postulated a new pathway in which HDGF activated HIF-1α and then induced VEGF expression through binding to membrane nucleolin under normoxic conditions, leading to poor disease control. The HDGF/HIF-1α/VEGF axis is important for developing future therapeutic strategies.

Citing Articles

Bovine Lactoferrin Enhances Toll-like Receptor 7 Response in Plasmacytoid Dendritic Cells and Modulates Cellular Immunity.

Yago T, Tada A, Kubo S, Oda H, Iwabuchi S, Tanaka M Int J Mol Sci. 2025; 25(24.

PMID: 39769133 PMC: 11676446. DOI: 10.3390/ijms252413369.

Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics.

Hu L, Wang X, Song Z, Chen F, Wu B Mol Med. 2024; 30(1):231.

PMID: 39592929 PMC: 11590533. DOI: 10.1186/s10020-024-00996-4.

Identification of a 5-gene signature panel for the prediction of prostate cancer progression.

Shen M, Garcia-Marques F, Muruganantham A, Liu S, White J, Bermudez A Br J Cancer. 2024; 131(11):1748-1761.

PMID: 39402324 PMC: 11589118. DOI: 10.1038/s41416-024-02854-w.

Solanine Inhibits Proliferation and Angiogenesis and Induces Apoptosis through Modulation of EGFR Signaling in KB-ChR-8-5 Multidrug-Resistant Oral Cancer Cells.

Prasad P, Jaber M, Awad Alahmadi T, S Almoallim H, Ramu A J Clin Med. 2024; 13(15).

PMID: 39124760 PMC: 11313312. DOI: 10.3390/jcm13154493.

Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts.

Zhou C, Li A, Ri K, Sultan A, Ren H Cancer Res Commun. 2024; 4(9):2308-2319.

PMID: 39041204 PMC: 11370239. DOI: 10.1158/2767-9764.CRC-24-0020.

References

Gray M, Zhang J, Ellis L, Semenza G, Evans D, Watowich S . HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005; 24(19):3110-20. DOI: 10.1038/sj.onc.1208513. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View

Brown J, Shaw R, Bekiroglu F, Rogers S . Systematic review of the current evidence in the use of postoperative radiotherapy for oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2011; 50(6):481-9. DOI: 10.1016/j.bjoms.2011.08.014. View

Ridiandries A, Tan J, Bursill C . The Role of CC-Chemokines in the Regulation of Angiogenesis. Int J Mol Sci. 2016; 17(11). PMC: 5133856. DOI: 10.3390/ijms17111856. View

Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604-13. PMC: 231459. DOI: 10.1128/MCB.16.9.4604. View

Tong Q, Zheng L, Lin L, Li B, Wang D, Huang C . VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-kappaB signaling pathway. Respir Res. 2006; 7:37. PMC: 1434739. DOI: 10.1186/1465-9921-7-37. View

Lin Y, Li C, Chen H, Yen C, Lin L, Huang C . The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012; 48(7):629-35. DOI: 10.1016/j.oraloncology.2012.01.014. View

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

10.

Funk G, Karnell L, Robinson R, Zhen W, Trask D, Hoffman H . Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck. 2002; 24(2):165-80. DOI: 10.1002/hed.10004. View

11.

Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M . Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 2001; 277(12):10315-22. DOI: 10.1074/jbc.M111122200. View

12.

Hsu H, Wall N, Hsueh C, Kim S, Ferris R, Chen C . Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 2013; 50(1):19-26. DOI: 10.1016/j.oraloncology.2013.10.003. View

13.

Boonkitticharoen V, Kulapaditharom B, Leopairut J, Kraiphibul P, Larbcharoensub N, Cheewaruangroj W . Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2008; 134(12):1305-11. DOI: 10.1001/archotol.134.12.1305. View

14.

Goradel N, Asghari M, Moloudizargari M, Negahdari B, Haghi-Aminjan H, Abdollahi M . Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol. 2017; 335:56-63. DOI: 10.1016/j.taap.2017.09.022. View

15.

Li S, Zhao Y, Cao W, Qu Y, Luo P, Zhen H . The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med Oncol. 2013; 30(3):622. DOI: 10.1007/s12032-013-0622-8. View

16.

Carmeliet P . Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6(4):389-95. DOI: 10.1038/74651. View

17.

Kyzas P, Cunha I, Ioannidis J . Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005; 11(4):1434-40. DOI: 10.1158/1078-0432.CCR-04-1870. View

18.

Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y . A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A. 1997; 94(9):4273-8. PMC: 20712. DOI: 10.1073/pnas.94.9.4273. View

19.

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S . Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005; 24(36):5552-60. DOI: 10.1038/sj.onc.1208719. View

20.

Sauter E, Nesbit M, Watson J, Klein-Szanto A, Litwin S, Herlyn M . Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999; 5(4):775-82. View